Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …
collaborative drug discovery efforts took place in academia and industry, culminating in …
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
G Li, E De Clercq - Nature reviews Drug discovery, 2020 - nature.com
Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer's oral drug nirmatrelvir.
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main
protease (Mpro) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in …
protease (Mpro) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in …
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started
to circulate among humans around December 2019, and it is now widespread as a global …
to circulate among humans around December 2019, and it is now widespread as a global …
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
H Lu - Bioscience trends, 2020 - jstage.jst.go.jp
As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have
been reported in 25 provinces (districts and cities) in China (1). Among them, 95 cases were …
been reported in 25 provinces (districts and cities) in China (1). Among them, 95 cases were …
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiological agent
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
L Fu, F Ye, Y Feng, F Yu, Q Wang, Y Wu, C Zhao… - Nature …, 2020 - nature.com
COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global
public health. The coronavirus main protease (Mpro, also called 3CLpro) is essential for …
public health. The coronavirus main protease (Mpro, also called 3CLpro) is essential for …
Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019‐nCoV
With the current trajectory of the 2019‐nCoV outbreak unknown, public health and medicinal
measures will both be needed to contain spreading of the virus and to optimize patient …
measures will both be needed to contain spreading of the virus and to optimize patient …
α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment
L Zhang, D Lin, Y Kusov, Y Nian, Q Ma… - Journal of medicinal …, 2020 - ACS Publications
The main protease of coronaviruses and the 3C protease of enteroviruses share a similar
active-site architecture and a unique requirement for glutamine in the P1 position of the …
active-site architecture and a unique requirement for glutamine in the P1 position of the …